Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial. [electronic resource]
Producer: 20170802Description: 5-12 p. digitalISSN:- 1468-1293
- Adult
- Anti-HIV Agents -- administration & dosage
- Antiretroviral Therapy, Highly Active -- adverse effects
- Darunavir -- administration & dosage
- Drug-Related Side Effects and Adverse Reactions -- epidemiology
- Female
- Humans
- Male
- Middle Aged
- Reverse Transcriptase Inhibitors -- administration & dosage
- Ritonavir -- administration & dosage
- Treatment Outcome
- Viral Load
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.